Survivin silencing as a promising strategy to enhance the sensitivity of cancer cells to chemotherapeutic agents

Molecular Pharmaceutics

Volumn 8, Issue 4, 2011, Pages 1120-1131

  Trabulo, S ^a,b   Cardoso, A M ^a,b   Santos Ferreira, T ^a,b   Cardoso, A L ^a,b   Simoes S ^b,c   Pedroso De Lima, M C ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b Faculty of Science and Technology   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

apoptosis; cancer gene therapy; chemotherapy; doxorubicin; RNA interference; survivin; vinblastine

Indexed keywords

CASPASE 3; CASPASE 7; DOXORUBICIN; SMALL INTERFERING RNA; SURVIVIN; VINBLASTINE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CELL PROLIFERATION; CELL VIABILITY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; RNA INTERFERENCE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; FLOW CYTOMETRY; HELA CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; VINBLASTINE;

EID: 79961082146     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100426e     Document Type: Article

References (60)

1. Fesik, S. W. Promoting apoptosis as a strategy for cancer drug discovery Nat. Rev. Cancer 2005, 5 (11) 876-85 (Pubitemid 41746032)
2. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer Cell 2000, 100 (1) 57-70 (Pubitemid 30046295)
3. Agarwal, R.; Kaye, S. B. Ovarian cancer: strategies for overcoming resistance to chemotherapy Nat. Rev. Cancer 2003, 3 (7) 502-16 (Pubitemid 37328838)
4. Okada, H.; Mak, T. W. Pathways of apoptotic and non-apoptotic death in tumour cells Nat. Rev. Cancer 2004, 4 (8) 592-603 (Pubitemid 39025054)
5. Hengartner, M. O. The biochemistry of apoptosis Nature 2000, 407 (6805) 770-6
6. Zhivotovsky, B.; Orrenius, S. Carcinogenesis and apoptosis: paradigms and paradoxes Carcinogenesis 2006, 27 (10) 1939-45 (Pubitemid 44530567)
7. Igney, F. H.; Krammer, P. H. Death and anti-death: tumour resistance to apoptosis Nat. Rev. Cancer 2002, 2 (4) 277-88 (Pubitemid 37328781)
8. Altieri, D. C. Validating survivin as a cancer therapeutic target Nat. Rev. Cancer 2003, 3 (1) 46-54 (Pubitemid 37328886)
9. Schimmer, A. D. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice Cancer Res. 2004, 64 (20) 7183-90 (Pubitemid 39372048)
10. Fischer, U.; Schulze-Osthoff, K. New approaches and therapeutics targeting apoptosis in disease Pharmacol. Rev. 2005, 57 (2) 187-215 (Pubitemid 41043884)
11. Ryan, B. M.; O'Donovan, N.; Duffy, M. J. Survivin: a new target for anti-cancer therapy Cancer Treat. Rev. 2009, 35 (7) 553-62
12. Mesri, M.; Wall, N. R.; Li, J.; Kim, R. W.; Altieri, D. C. Cancer gene therapy using a survivin mutant adenovirus J. Clin. Invest. 2001, 108 (7) 981-90 (Pubitemid 32946072)
13. Tamm, I.; Wang, Y.; Sausville, E.; Scudiero, D. A.; Vigna, N.; Oltersdorf, T.; Reed, J. C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs Cancer Res. 1998, 58 (23) 5315-20 (Pubitemid 28551107)
14. Li, F.; Ambrosini, G.; Chu, E. Y.; Plescia, J.; Tognin, S.; Marchisio, P. C.; Altieri, D. C. Control of apoptosis and mitotic spindle checkpoint by survivin Nature 1998, 396 (6711) 580-4 (Pubitemid 28563719)
15. Hoffman, W. H.; Biade, S.; Zilfou, J. T.; Chen, J.; Murphy, M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53 J. Biol. Chem. 2002, 277 (5) 3247-57 (Pubitemid 34953189)
16. Beltrami, E.; Plescia, J.; Wilkinson, J. C.; Duckett, C. S.; Altieri, D. C. Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis J. Biol. Chem. 2004, 279 (3) 2077-84 (Pubitemid 38084480)
17. Dohi, T.; Beltrami, E.; Wall, N. R.; Plescia, J.; Altieri, D. C. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis J. Clin. Invest. 2004, 114 (8) 1117-27 (Pubitemid 39578701)
18. Liu, T.; Biddle, D.; Hanks, A. N.; Brouha, B.; Yan, H.; Lee, R. M.; Leachman, S. A.; Grossman, D. Activation of dual apoptotic pathways in human melanocytes and protection by survivin J. Invest. Dermatol. 2006, 126 (10) 2247-56 (Pubitemid 44413172)
19. Li, F.; Ackermann, E. J.; Bennett, C. F.; Rothermel, A. L.; Plescia, J.; Tognin, S.; Villa, A.; Marchisio, P. C.; Altieri, D. C. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function Nat. Cell Biol. 1999, 1 (8) 461-6 (Pubitemid 129503664)
20. Uchida, H.; Tanaka, T.; Sasaki, K.; Kato, K.; Dehari, H.; Ito, Y.; Kobune, M.; Miyagishi, M.; Taira, K.; Tahara, H.; Hamada, H. Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo Mol. Ther. 2004, 10 (1) 162-71 (Pubitemid 38878158)
21. Altieri, D. C. Survivin, cancer networks and pathway-directed drug discovery Nat. Rev. Cancer 2008, 8 (1) 61-70
22. Duffy, M. J.; O'Donovan, N.; Brennan, D. J.; Gallagher, W. M.; Ryan, B. M. Survivin: a promising tumor biomarker Cancer Lett. 2007, 249 (1) 49-60 (Pubitemid 46442669)
23. Yonesaka, K.; Tamura, K.; Kurata, T.; Satoh, T.; Ikeda, M.; Fukuoka, M.; Nakagawa, K. Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin Int. J. Cancer 2006, 118 (4) 812-20 (Pubitemid 43157656)
24. Olie, R. A.; Simoes-Wust, A. P.; Baumann, B.; Leech, S. H.; Fabbro, D.; Stahel, R. A.; Zangemeister-Wittke, U. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy Cancer Res. 2000, 60 (11) 2805-9 (Pubitemid 30395796)
25. Kappler, M.; Taubert, H.; Bartel, F.; Blumke, K.; Panian, M.; Schmidt, H.; Dunst, J.; Bache, M. Radiosensitization, after a combined treatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wt-p53 sarcoma cell line, but not in a mt-p53 sarcoma cell line Oncol. Rep. 2005, 13 (1) 167-72
26. Obexer, P.; Hagenbuchner, J.; Unterkircher, T.; Sachsenmaier, N.; Seifarth, C.; Bock, G.; Porto, V.; Geiger, K.; Ausserlechner, M. Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis Mol. Biol. Cell 2009, 20 (7) 2041-8
27. Carvalho, A.; Carmena, M.; Sambade, C.; Earnshaw, W. C.; Wheatley, S. P. Survivin is required for stable checkpoint activation in taxol-treated HeLa cells J. Cell Sci. 2003, 116 (Part 14) 2987-98 (Pubitemid 36926987)
28. Dalby, B.; Cates, S.; Harris, A.; Ohki, E. C.; Tilkins, M. L.; Price, P. J.; Ciccarone, V. C. Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications Methods 2004, 33 (2) 95-103 (Pubitemid 38569654)
29. Pai, S. I.; Lin, Y. Y.; Macaes, B.; Meneshian, A.; Hung, C. F.; Wu, T. C. Prospects of RNA interference therapy for cancer Gene Ther. 2006, 13 (6) 464-77
30. Li, S. D.; Huang, L. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells Mol. Pharmaceutics 2006, 3 (5) 579-88 (Pubitemid 44639135)
31. Ryther, R. C.; Flynt, A. S.; Phillips, J. A., 3rd; Patton, J. G. siRNA therapeutics: big potential from small RNAs Gene Ther. 2005, 12 (1) 5-11 (Pubitemid 40090039)
32. de Fougerolles, A. R. Delivery vehicles for small interfering RNA in vivo Hum. Gene Ther. 2008, 19 (2) 125-32 (Pubitemid 351278372)
33. Oh, Y. K.; Park, T. G. siRNA delivery systems for cancer treatment Adv Drug Delivery Rev. 2009, 61 (10) 850-62
34. Weinstein, I. B.; Joe, A. K. Mechanisms of disease: Oncogene addiction - a rationale for molecular targeting in cancer therapy Nat. Clin. Pract. Oncol. 2006, 3 (8) 448-57 (Pubitemid 44203817)
35. Caplen, N. J. Gene therapy progress and prospects. Downregulating gene expression: the impact of RNA interference Gene Ther. 2004, 11 (16) 1241-8 (Pubitemid 39173430)
36. Dai, Y.; Lawrence, T. S.; Xu, L. Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B Am. J. Transl. Res. 2009, 1 (1) 1-15
37. Paduano, F.; Villa, R.; Pennati, M.; Folini, M.; Binda, M.; Daidone, M. G.; Zaffaroni, N. Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17- demethoxygeldanamycin in human prostate cancer cells Mol. Cancer Ther. 2006, 5 (1) 179-86
38. Pennati, M.; Binda, M.; De Cesare, M.; Pratesi, G.; Folini, M.; Citti, L.; Daidone, M. G.; Zunino, F.; Zaffaroni, N. Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo Carcinogenesis 2004, 25 (7) 1129-36 (Pubitemid 38968040)
39. Pennati, M.; Binda, M.; Colella, G.; Zoppe, M.; Folini, M.; Vignati, S.; Valentini, A.; Citti, L.; De Cesare, M.; Pratesi, G.; Giacca, M.; Daidone, M. G.; Zaffaroni, N. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells Oncogene 2004, 23 (2) 386-94 (Pubitemid 38174992)
40. Grossman, D.; Kim, P. J.; Schechner, J. S.; Altieri, D. C. Inhibition of melanoma tumor growth in vivo by survivin targeting Proc. Natl. Acad. Sci. U.S.A. 2001, 98 (2) 635-40 (Pubitemid 32105095)
41. Zhang, M.; Mukherjee, N.; Bermudez, R. S.; Latham, D. E.; Delaney, M. A.; Zietman, A. L.; Shipley, W. U.; Chakravarti, A. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo Prostate 2005, 64 (3) 293-302 (Pubitemid 40980871)
42. Gagnon, V.; Van Themsche, C.; Turner, S.; Leblanc, V.; Asselin, E. Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol Apoptosis 2008, 13 (2) 259-71
43. Wall, N. R.; O'Connor, D. S.; Plescia, J.; Pommier, Y.; Altieri, D. C. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis Cancer Res. 2003, 63 (1) 230-5 (Pubitemid 36070444)
44. Venkatesan, B.; Prabhu, S. D.; Venkatachalam, K.; Mummidi, S.; Valente, A. J.; Clark, R. A.; Delafontaine, P.; Chandrasekar, B. WNT1-inducible signaling pathway protein-1 activates diverse cell survival pathways and blocks doxorubicin-induced cardiomyocyte death Cell. Signalling 2010, 22 (5) 809-20
45. Stewart, D. J. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer Crit. Rev. Oncol. Hematol. 2010, 75 (3) 173-234
46. Chu, R.; Upreti, M.; Ding, W. X.; Yin, X. M.; Chambers, T. C. Regulation of Bax by c-Jun NH2-terminal kinase and Bcl-xL in vinblastine-induced apoptosis Biochem. Pharmacol. 2009, 78 (3) 241-8
47. Kolomeichuk, S. N.; Bene, A.; Upreti, M.; Dennis, R. A.; Lyle, C. S.; Rajasekaran, M.; Chambers, T. C. Induction of apoptosis by vinblastine via c-Jun autoamplification and p53-independent down-regulation of p21WAF1/CIP1 Mol. Pharmacol. 2008, 73 (1) 128-36 (Pubitemid 350294204)
48. Pennati, M.; Folini, M.; Zaffaroni, N. Targeting survivin in cancer therapy Expert Opin. Ther. Targets 2008, 12 (4) 463-76 (Pubitemid 351551639)
49. Altieri, D. C. Targeted therapy by disabling crossroad signaling networks: the survivin paradigm Mol. Cancer Ther. 2006, 5 (3) 478-82
50. Li, F.; Ling, X. Survivin study: an update of "what is the next wave"? J. Cell. Physiol. 2006, 208 (3) 476-86 (Pubitemid 44141872)
51. Lee, D.; Long, S. A.; Adams, J. L.; Chan, G.; Vaidya, K. S.; Francis, T. A.; Kikly, K.; Winkler, J. D.; Sung, C. M.; Debouck, C.; Richardson, S.; Levy, M. A.; DeWolf, W. E., Jr.; Keller, P. M.; Tomaszek, T.; Head, M. S.; Ryan, M. D.; Haltiwanger, R. C.; Liang, P. H.; Janson, C. A.; McDevitt, P. J.; Johanson, K.; Concha, N. O.; Chan, W.; Abdel-Meguid, S. S.; Badger, A. M.; Lark, M. W.; Nadeau, D. P.; Suva, L. J.; Gowen, M.; Nuttall, M. E. Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality J. Biol. Chem. 2000, 275 (21) 16007-14 (Pubitemid 30366906)
52. Porter, A. G.; Janicke, R. U. Emerging roles of caspase-3 in apoptosis Cell Death Differ. 1999, 6 (2) 99-104 (Pubitemid 29082297)
53. Shin, S.; Sung, B. J.; Cho, Y. S.; Kim, H. J.; Ha, N. C.; Hwang, J. I.; Chung, C. W.; Jung, Y. K.; Oh, B. H. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7 Biochemistry 2001, 40 (4) 1117-23 (Pubitemid 32108606)
54. Banks, D. P.; Plescia, J.; Altieri, D. C.; Chen, J.; Rosenberg, S. H.; Zhang, H.; Ng, S. C. Survivin does not inhibit caspase-3 activity Blood 2000, 96 (12) 4002-3
55. Conway, E. M.; Pollefeyt, S.; Steiner-Mosonyi, M.; Luo, W.; Devriese, A.; Lupu, F.; Bono, F.; Leducq, N.; Dol, F.; Schaeffer, P.; Collen, D.; Herbert, J. M. Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways Gastroenterology 2002, 123 (2) 619-31 (Pubitemid 34827205)
56. Li, C.; Wu, Z.; Liu, M.; Pazgier, M.; Lu, W. Chemically synthesized human survivin does not inhibit caspase-3 Protein Sci. 2008, 17 (9) 1624-9
57. Marusawa, H.; Matsuzawa, S.; Welsh, K.; Zou, H.; Armstrong, R.; Tamm, I.; Reed, J. C. HBXIP functions as a cofactor of survivin in apoptosis suppression EMBO J. 2003, 22 (11) 2729-40 (Pubitemid 36712369)
58. Dohi, T.; Okada, K.; Xia, F.; Wilford, C. E.; Samuel, T.; Welsh, K.; Marusawa, H.; Zou, H.; Armstrong, R.; Matsuzawa, S.; Salvesen, G. S.; Reed, J. C.; Altieri, D. C. An IAP-IAP complex inhibits apoptosis J. Biol. Chem. 2004, 279 (33) 34087-90 (Pubitemid 39318028)
59. Altieri, D. C. New wirings in the survivin networks Oncogene 2008, 27 (48) 6276-84
60. Liu, T.; Brouha, B.; Grossman, D. Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells Oncogene 2004, 23 (1) 39-48 (Pubitemid 38142238)